JOHN GRAHAM

John Graham is the Chief Executive Officer of Zuellig Pharma,
covering 16 markets with over 12,000 employees. The organisation
serves more than 200,000 medical facilities and works with over 450
clients, including the top 20 pharmaceutical companies in the world,
with the goal of providing a full spectrum of innovative and
integrated solutions across the healthcare value chain.

John has led the development and growth of the ZP Therapeutics
business at Zuellig Pharma, prior to becoming Chief Executive
Officer, spearheading the growth of its marketing, sales, business
development and regulatory services.

Prior to joining Zuellig Pharma, John was Chief Executive Officer of
the Invida Group, Singapore. Invida was a Pan-Asian specialty
pharma company focused on the development, marketing and
distribution of biopharmaceuticals and medical devices in 15 Asian
countries. During his tenure, John transformed and executed the
sale of the company in 2011 to the Menarini Group, Italy’s largest
pharma company. The company continued to thrive under his
leadership, as Menarini Asia Pacific, until his departure in December
2015.

John started his career with Aventis, where he spent 18 years in
various operational and global leadership positions including
regional responsibilities in Latin America, Head of Global Diabetes,
and Global VP of New Products. Following that, he was Managing
Director of Genzyme's operations in Germany and Switzerland
before building up a Life Sciences Advisory Practice at Ernst &
Young. He brings with him over 30 years of experience in biotech,
pharmaceuticals and healthcare consulting.

He is British and currently is based in Singapore.